Feb 01,2024

AI can Predict Brain Cancer Patients' Survival

Researchers at King's College London have utilized artificial intelligence (AI) to predict the survival of adult patients with glioblastoma, a challenging brain cancer, within eight months after receiving radiotherapy. The deep learning model, trained on a dataset of 10,000s of brain cancer scans, demonstrated improved accuracy in predicting outcomes compared to traditional methods. The AI offers an immediate and accurate prediction from routine MRI scans, allowing clinicians to identify patients who may not benefit from chemotherapy, enabling a shift to alternative treatments or clinical trials. The study addresses the need for better outcomes in brain cancer patients and empowers individuals to make informed decisions about their treatment.

CLINICAL STUDY

#ai/software

View Analyst & Ambassador Comments
Go to original news
Jan 30,2024 TOP STORY

Reimagine Care and Michiana Hematology Oncology Partnership Extends Cancer Care into the Homes of Patients of the Largest Cancer Provider in the Region

Reimagine Care, the nation’s leading provider of virtual-first cancer care, announces a partnership with Michiana Hematology Oncology (MHO) to extend its cancer care services beyond the walls of the clinic. This partnership represents a significant step towards a more patient-centric treatment experience by integrating clinical oncology experts with technology to support MHO’s patients around the clock. By combining Reimagine Care's virtual, digital, and data capabilities with MHO's expertise in hematology and oncology, the collaboration aims to break down barriers to access and transform the way patients receive treatment. MHO patients will have the ability discuss treatment plans, ask questions, manage symptoms, and receive personalized care with Reimagine Care’s oncology advanced practice providers and registered nurses through SMS text, call, and video consultations.

COLLABORATION PARTNERSHIP

#institution

#virtual care

#rpm

View Analyst & Ambassador Comments
Go to original news
Jan 30,2024

PathAI launches six additional oncology indications for PathExplore, an AI-powered pathology panel for spatial analysis of the tumor microenvironment

PathAI, a leading AI-powered pathology firm, has expanded PathExploreTM, the world's first standardized panel for tumor microenvironment (TME) characterization from H&E-stained whole-slide images. The six new oncology indications include ovarian, bladder, liver, small cell lung, lymphoma, and head and neck cancers. Initially launched in April 2023 with 8 indications, PathExplore now covers a total of 14 oncology indications, including non-small cell lung, breast, colorectal, skin, gastric, prostate, kidney, and pancreatic cancers. This expansion enhances the availability of PathExplore's human interpretable features (HIFs), advancing precision oncology efforts.

PRODUCT

#ai/software

#clinical decision support

View Analyst & Ambassador Comments
Go to original news
Jan 22,2024

Development and pre-pilot testing of STAMP+CBT: an mHealth app combining pain cognitive behavioral therapy and opioid support for patients with advanced cancer and pain

The researchers have developed and piloted a mobile health the STAMP+CBT app to deliver cognitive behavioral therapy for pain (pain-CBT), remote symptom monitoring, and pharmacologic support for patients with pain from advanced cancer. The app delivers brief daily lessons from pain-CBT and pain psychoeducation, adapted for advanced cancer. Daily surveys assess physical symptoms, psychological symptoms, opioid utilization and relief. Just-in-time adaptive interventions generate tailored psychoeducation in response. They then conducted a single-arm pilot feasibility study at two cancer centers. Patients with advanced cancer and chronic pain used the app for 2 or 4 weeks, rated its acceptability and provided feedback in semi-structured interviews. Fifteen participants tested the app. Feasibility and acceptability were defined as 70% of participants completing 50% of daily surveys, and 80% of acceptability items rated 4/5. The results showed 73% of patients completed 50% of daily surveys; 87% of acceptability items were rated 4/5. Participants valued the app’s brevity, clarity, and salience, and found education on stress and pain to be most helpful.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jan 25,2024 TOP STORY

Patient Risk Management Platform, Wave Health, Delivers Rare 93% Patient Compliance And 98% HCP Perceived Usefulness

Treatment Technologies & Insights (TTI) announced significant results from an eight-hospital, three-month study in Spain focusing on prostate cancer patients undergoing systemic therapy. In the PRO-WAVE1 study using the Wave Health App, patients engaged in a 13-week period completing a weekly symptom review (WSR). The study, accepted for presentation at the 2024 ASCO GU Symposium, revealed that care teams, comprising nurse coordinators and treating physicians, found the platform highly valuable, with 98% rating it useful. Additionally, 90% perceived a positive impact on communication, and 85% saw it addressing emerging patient issues. Among patients, 93% showed compliance, 93% were satisfied, and 84% accepted the app. Notably, a positive relationship was observed between app usage and emotional wellbeing, with active users experiencing a statistically significant increase. The study also uncovered progressing adverse events, emphasizing the platform's role in promptly identifying and addressing potential issues proactively.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jan 19,2024

Quibim adds new AI cancer detection capability to prostate tool

Quibim, a company using imaging biomarkers for precision medicine, has added a new cancer detection capability to its prostate tool based on AI, QP-Prostate. The updated product, which uses algorithms trained on actual pathology data as ground truth, has been given a CE mark for the European Union and a UKCA mark for the United Kingdom. This is an industry-first and will help radiologists enhance diagnostic accuracy in terms of high specificity beyond high sensitivity as well as shortened reporting times.

PRODUCT

#ai/software

#clinical decision support

View Analyst & Ambassador Comments
Go to original news
Jan 24,2024

Live tumor imaging company Elephas garners $55M

Elephas, an oncology-focused diagnostics platform, announced it secured $55 million in Series C funding, bringing its total raise to $116.5 million. Venture Investors Health Fund and the State of Wisconsin Investment Board (SWIB) led the round. Existing investors Northpond Ventures, Moore Strategic Ventures, WARF Ventures, Tao Invest, Sands Capital and ARCH Ventures also participated in the raise. Elephas is developing a diagnostics platform to predict a patient's response to immunotherapy using metabolic imaging. The Wisconsin-based company analyzes a tumor's architecture via a patient biopsy and treats it with potential therapies to determine treatment response.

FUNDING SERIES C
View Analyst & Ambassador Comments
Go to original news
Jan 23,2024

AI Harnesses Tumor Genetics to Predict Treatment Response

Scientists at University of California San Diego School of Medicine leveraged a machine learning algorithm to tackle one of the biggest challenges facing cancer researchers: predicting when cancer will resist chemotherapy. The algorithm, trained on 718 genes commonly used in cancer genetic testing, successfully predicted responses to cisplatin in cervical cancer tumors. Unlike previous models, it considers broader biochemical networks crucial for cancer survival. The model's transparency in decision-making, identifying protein assemblies influencing treatment resistance, enhances trust and offers potential new targets for chemotherapy. The researchers believe the model has broad applications in improving current cancer treatment and pioneering new approaches.

CLINICAL STUDY

#ai/software

View Analyst & Ambassador Comments
Go to original news
Jan 18,2024 TOP STORY

Aptar Digital Health and Moffitt Cancer Center Launch Clinical Evaluation for Oncology Digital Therapeutic, Oleena®

Aptar Digital Health announced a collaboration with Moffitt Cancer Center, a leading U.S. cancer care and research institution, to conduct a clinical evaluation of Oleena®, Aptar Digital Health’s FDA approved and CE-marked digital therapeutic (DTx) for the management of symptoms in cancer care. The clinical evaluation, which will begin in February 2024 and run for a total period of 15 months, will primarily assess the usability of Oleena® by measuring key indicators such as patient satisfaction and engagement, as well as clinical outcomes including symptom burden, anti-cancer treatment adherence and quality of life. Under this clinical evaluation, head and neck cancer patients being treated with chemoradiation will use Aptar Digital Health’s Oleena® DTx to guide them in self-managing their symptoms.

COLLABORATION PARTNERSHIP

#r&d

#dtx

#rpm

View Analyst & Ambassador Comments
Go to original news
Jan 04,2024

Aptar Digital Health and Gerresheimer Collaborate to Develop Integrated Solution for Subcutaneous Cancer Therapy

Aptar Digital Health announced a new collaboration with Gerresheimer, an innovative systems and solutions provider and global partner to the pharma, biotech and cosmetics industries, to develop a tailored solution to support patients and health care professionals in cancer therapy management. By connecting Aptar Digital Health’s proprietary SaMD platform with Gx SensAir, Gerresheimer’s on-body device for the subcutaneous delivery of large biologics molecules, this integrated solution is intended to improve overall treatment adherence and clinical outcomes. More specifically, it aims to make remote patient monitoring easier, and facilitate the onboarding of patients to new therapies, helping them to better manage adverse effects. For pharmaceutical companies, this collaboration is an opportunity to offer a more patient-centric solution, and tackle potential challenges, such as treatment interruptions or discontinuations related to administration issues or adverse effects. This solution will also support the transition from intravenous to subcutaneous administration of oncology drugs. This integrated solution will first be designed for targeted anti-cancer therapies such as PD-1/PDL-1, CTLA-4, with the potential to expand to all therapies delivered subcutaneously.

COLLABORATION PARTNERSHIP

#r&d

#connected device

#rpm

View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY